Analysts Set Expectations for TSE:GUD Q2 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Research analysts at Stifel Canada issued their Q2 2025 EPS estimates for Knight Therapeutics in a research note issued to investors on Monday, March 24th. Stifel Canada analyst J. Keywood expects that the company will post earnings of $0.04 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ FY2025 earnings at $0.17 EPS.

GUD has been the topic of a number of other reports. Canaccord Genuity Group lowered Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. Research Capitl upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Finally, Stifel Nicolaus increased their price objective on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Knight Therapeutics presently has a consensus rating of “Buy” and a consensus price target of C$7.48.

Knight Therapeutics Stock Performance

Shares of GUD opened at C$6.01 on Wednesday. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. Knight Therapeutics has a one year low of C$5.09 and a one year high of C$6.45. The company’s fifty day moving average price is C$5.71 and its 200 day moving average price is C$5.59. The company has a market capitalization of C$607.91 million, a PE ratio of -20.06, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insider Buying and Selling at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan sold 2,500,000 shares of the business’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of C$6.30, for a total value of C$15,750,000.00. Insiders sold a total of 3,143,300 shares of company stock valued at $19,733,740 in the last quarter. Corporate insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.